Geron Quick Ratio (GERN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Geron Corporation  (NASDAQ: GERN)

Geron's Quick Ratio

GERN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.92 below Geron's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 358 other companies have achieved higher Quick Ratio than Geron in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1581 to 2044.

Explain Quick Ratio?
How much Cash & cash equivalents GERN´s has?
What are GERN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GERN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 9.41 % 16.71 % 26.32 % -36.41 % -37.91 %
Y / Y Cash & cash equivalent Change -18.62 % -17.32 % -2.57 % -76.58 % -78.12 %
Quick Ratio MRQ 0.92 0.96 0.71 0.91 1.24
GERN's Total Ranking # 2044 # 1581 # 1259 # 1514 # 1217
Seq. Current Liabilities Change -4.4 % -34.04 % 27.17 % 36.45 % 1.98 %
Seq. Cash & cash equivalent Change -8.47 % -10.9 % -0.69 % 0.49 % -7.02 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 359
Healthcare Sector # 642
Overall Market # 2044


Quick Ratio Statistics
High Average Low
51.83 13.02 0.71
(Jun 30 2017)   (Dec 31 2025)




Financial Statements
Geron's Current Liabilities $ 70 Millions Visit GERN's Balance sheet
Geron's Cash & cash equivalent $ 65 Millions Visit GERN's Balance sheet
Source of GERN's Sales Visit GERN's Sales by Geography


Cumulative Geron's Quick Ratio

GERN's Quick Ratio for the trailling 12 Months

GERN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -2.94 % -14.18 % -27.9 % -35.83 % -16.65 %
Y / Y Cash & cash equivalent TTM Growth -49.86 % -64.5 % -73.63 % -77.99 % -59.61 %
Quick Ratio TTM 0.86 0.92 0.99 1.08 1.66
Total Ranking TTM # 3981 # 2831 # 2076 # 2840 # 2910
Seq. Current Liabilities TTM Growth 1.79 % 3.23 % 7.66 % -14.2 % -9.99 %
Seq. Cash & cash equivalent TTM Growth -4.78 % -4.57 % -0.64 % -44.47 % -32.57 %

Quick ratio ranking by company, industry and sector >> Back to GERN Financial Strength Comparisons >> Go to Compare GERN Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2026 to $70.33 millions, cumulative Quick Ratio decreased to 0.86 below the Geron Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Geron. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2831 to 3981.

Explain Quick Ratio?
How much Cash & cash equivalents GERN´s has?
What are GERN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 897
Within the Market # 3981


trailing twelve months Quick Ratio Statistics
High Average Low
2.82 1.32 0.59
(Sep 30 2018)   (Jun 30 2015)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Beone Medicines Ltd   2.50 $ 5,290.368  Millions$ 2,119.187  Millions
Ironwood Pharmaceuticals inc   2.41 $ 79.127  Millions$ 32.854  Millions
Schrodinger Inc   2.38 $ 413.739  Millions$ 173.845  Millions
Insmed Inc  2.37 $ 1,160.312  Millions$ 490.508  Millions
Biovie Inc   2.37 $ 8.977  Millions$ 3.796  Millions
Tao Synergies Inc   2.30 $ 2.368  Millions$ 1.032  Millions
Madrigal Pharmaceuticals Inc   2.24 $ 839.419  Millions$ 374.204  Millions
Rockwell Medical inc   2.23 $ 24.936  Millions$ 11.174  Millions
Ars Pharmaceuticals Inc   2.22 $ 143.845  Millions$ 64.728  Millions
Alnylam Pharmaceuticals Inc   2.19 $ 3,308.147  Millions$ 1,512.513  Millions
Xeris Biopharma Holdings Inc   2.16 $ 243.494  Millions$ 112.826  Millions
Ardelyx inc   2.13 $ 281.830  Millions$ 132.220  Millions
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions

Date modified: 2026-09-12T18:31:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.